Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

This is a retrospective chart-review study that will be based on the collection of data from electronical or paper-based medical records with available data on patients who have commenced treatment with fulvestrant after January 1st of 2007. All necessary information for the purposes of the present study will be collected with the use of a paper-Case Record Form.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hellenic Oncology Research Group
• Treatments: Estradiol; Fulvestrant

Criteria

Inclusion Criteria:

• Postmenopausal women with ER-positive and/or PgR-positive breast cancer who have failed at least one prior endocrine therapy, either as adjuvant treatment or for the treatment of advanced disease

• Patients who have received treatment with fulvestrant for metastatic breast cancer and have completed/discontinued the treatment regardless of outcome/reason for discontinuation (except for treatment discontinuation for non-clinical reasons)

• Patients who were at postmenopausal status at the time of treatment with fulvestrant

Exclusion Criteria:

• Patients who are currently undergoing treatment with fulvestrant

• Investigators/treating physicians with no available electronical or paper-based medical records